hKSR-2, a vitamin D-regulated gene, inhibits apoptosis in arabinocytosine-treated HL60 leukemia cells.
Ras signaling can be modulated by the scaffolding activity of kinase suppressor of Ras-1 (KSR-1) and by the hKSR-2 protein, resulting in diverse phenotypic outcomes. The mitogen-activated protein kinase cascade downstream from Ras and KSRs includes Raf-1 and extracellular signal-regulated kinase 1/2 kinases, known to enhance survival potential of a range of cell types. Because the molecular events that increase survival of HL60 cells induced to differentiate toward monocytic phenotype by 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] are not known, we investigated if KSR proteins provide a survival function in these cells. We found that whereas kinase suppressor of Ras-1 had no detectable effect on cell survival in the system studied here, 1,25-(OH)2D3-induced up-regulation of hKSR-2 enhanced the resistance of HL60 cells to arabinocytosine. Knockdown of hKSR-2 by either small interfering RNA or antisense oligonucleotides increased arabinocytosine-induced apoptosis, which was accompanied by reduced Bcl-2/Bax and Bcl-2/Bad ratios, and increased caspase-3 activating cleavage. In contrast, up-regulation of Mcl-1 was not abrogated by anti-sense (AS) AS-hKSR-2, pointing to a specific role of Bcl-2 in control of 1,25-(OH)2D3-induced increased cell survival. These findings are consistent with the previously shown lack of fully differentiated monocytic cells in HL60 cultures exposed to 1,25-(OH)2D3 in which hKSR-2 was knocked down, suggesting that optimal differentiation of these cells requires enhanced antiapoptotic mechanisms provided, at least in part, by hKSR-2. Collectively, these results suggest that hKSR-2 may offer a new target for novel therapies of acute myelogenous leukemia.
Wang
Xuening
X
Department of Pathology and Laboratory Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA.
Patel
Rahul
R
Studzinski
George P
GP
D000111:Acetylcysteine / Q000494:pharmacology; D048868:Adaptor Proteins, Signal Transducing / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D003561:Cytarabine / Q000633:toxicity*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009336:Necrosis; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000378:metabolism; D014807:Vitamin D / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology
D048868:Adaptor Proteins, Signal Transducing; D000975:Antioxidants; C479421:CNKSR2 protein, human; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C118756:dihydroxy-vitamin D3; D003561:Cytarabine; D014807:Vitamin D; D000111:Acetylcysteine
Blood. 1979 Sep;54(3):713-33
288488
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12792-6
9371754
Curr Biol. 2004 Apr 6;14(7):R277-8
15062121
Oncogene. 2006 Nov 9;25(53):7078-85
16732322
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50
18032601
Oncogene. 1994 Sep;9(9):2751-6
8058342
J Neurosci. 2007 Oct 17;27(42):11389-400
17942733
Mol Pharmacol. 2006 Jan;69(1):288-98
16219908
J Cell Biochem. 2001;80(4):471-82
11169731
Blood. 1983 Oct;62(4):709-21
6192859
Blood. 1990 Nov 1;76(9):1704-9
2224119
J Cell Physiol. 2004 Mar;198(3):333-42
14755538
Cell. 1995 Dec 15;83(6):879-88
8521512
Proc Natl Acad Sci U S A. 1981 Aug;78(8):4990-4
6946446
Cancer Res. 1997 Jan 1;57(1):62-7
8988042
J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):47-55
16046262
J Cell Physiol. 1996 Mar;166(3):523-36
8600156
Curr Biol. 2002 Mar 5;12(5):427-33
11882296
Curr Biol. 2002 Apr 30;12(9):R325-7
12007434
Br J Pharmacol. 2007 Sep;152(2):249-55
17618303
J Clin Invest. 2004 Nov;114(9):1272-80
15520859
Nat Rev Mol Cell Biol. 2005 Nov;6(11):827-37
16227978
J Cell Physiol. 2006 Nov;209(2):253-60
16883571
Exp Cell Res. 2007 Aug 15;313(14):3034-45
17599832
Cancer Res. 2001 Feb 15;61(4):1533-40
11245462
J Biol Chem. 2003 Nov 21;278(47):47089-97
12975377
Anticancer Res. 2001 Jan-Feb;21(1A):499-504
11299787
Leukemia. 1996 Jul;10(7):1143-9
8683994
Leukemia. 1994 May;8(5):806-15
8182938
Anticancer Res. 1998 Jul-Aug;18(4A):2327-38
9703875
Cancer Res. 2005 May 15;65(10):3986-92
15899786
Med Oncol. 1999 Apr;16(1):58-64
10382944
Science. 1995 Nov 24;270(5240):1326-31
7481820
J Biol Chem. 2004 Jun 18;279(25):26210-4
15084597
Toxicol Lett. 2004 Sep 10;152(2):149-58
15302096
Genes Dev. 2002 Feb 15;16(4):427-38
11850406
Methods Cell Biol. 1995;46:153-85
7541883
Curr Pharm Des. 2004;10(8):855-66
15032689
Leukemia. 1995 May;9(5):789-98
7769841
Science. 2005 Feb 18;307(5712):1101-4
15718471
Cancer Res. 2008 Jan 15;68(2):395-403
18199533
Biochem Biophys Res Commun. 2005 Sep 9;334(4):1214-8
16039990
Mol Cell Biol. 1997 Jun;17(6):3229-41
9154822
Exp Cell Res. 1997 Aug 25;235(1):210-7
9281370